Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opdivo + Chemo + Bevacizumab in non-squamous NSCLC
NCT03117049Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2017
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing ONO-4538 group with Placebo group (2 arms). Primary endpoint: Progression Free Survival at 32 months. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03117049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03117049.